07:00 , Aug 11, 2014 |  BC Week In Review  |  Company News

Symplmed, Lannett deal

Symplmed granted Lannett exclusive rights to distribute an authorized generic of 2, 4 and 8 mg Aceon perindopril erbumine in the U.S. Lannett said it plans to launch the product “shortly,” but declined to disclose...
07:00 , Sep 30, 2013 |  BioCentury  |  Emerging Company Profile

Symplmed: Skipping the middleman

The broad availability of low cost generics and the size of salesforce needed to cover the market have made hypertension a no-fly zone for most biotechs and even some pharmas. Symplmed Pharmaceuticals LLC is entering...
07:00 , Jul 15, 2013 |  BC Week In Review  |  Company News

Symplmed, Xoma deal

Symplmed acquired from Xoma exclusive, U.S. rights to develop and commercialize a fixed-dose combination of perindopril/amlodipine and a sublicense to promote Aceon perindopril erbumine in the U.S. Xoma will receive an undisclosed equity stake in...
07:00 , Jul 15, 2013 |  BioCentury  |  Finance

New Dyrction

Symplmed Pharmaceuticals LLC found an individual investor who has bought into the company's plan of introducing a disruptive sales strategy that incentivizes doctors and patients to use its blood pressure therapies. The newco, which spun...
08:00 , Dec 10, 2012 |  BC Week In Review  |  Clinical News

Coveram perindopril/amlopidine: Phase III data

Top-line data from the double-blind, U.S. Phase III PATH trial in 837 patients showed that once-daily oral Coveram produced significantly greater reductions in both seated DBP and SBP from baseline to week 6 compared to...
07:00 , May 14, 2012 |  BC Week In Review  |  Clinical News

Perindopril/amlodipine: Phase III started

In late February, Xoma began the double-blind, U.S. Phase III PATH trial to compare an oral fixed-dose combination of perindopril plus amlodipine once daily for 6 weeks vs. perindopril or amlodipine alone in about 816...
08:00 , Feb 6, 2012 |  BC Week In Review  |  Company News

Xoma, Servier sales and marketing update

Xoma gained U.S. commercialization rights to Servier's Aceon perindopril erbumine, as well as options to develop and commercialize up to three products in the U.S. combining perindopril with other cardiovascular drugs in fixed-dose combinations. Xoma...
07:00 , Oct 16, 2006 |  BC Week In Review  |  Company News

CV Therapeutics, Solvay sales and marketing update

The companies terminated their 2004 deal to co-promote SOLB's Aceon perindopril erbumine tablets in the U.S. to treat essential hypertension and to reduce the risk of cardiovascular mortality or non-fatal myocardial infarction (MI) in patients...
07:00 , Sep 12, 2005 |  BC Week In Review  |  Clinical News

Aceon perindopril erbumine cardiovascular data

Results from the double-blind, placebo-controlled PREAMI study in 1,252 elderly patients showed that Aceon reduced the combination of death, hospitalization for heart failure and LV remodeling by 38% (p<0.001). Of particular note, the reduction in...
07:00 , Aug 29, 2005 |  BC Week In Review  |  Clinical News

Aceon perindopril erbumine regulatory update

FDA approved an expanded label for Aceon to treat patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or non-fatal myocardial infarction (MI). The angiotensin-converting enzyme (ACE) inhibitor is marketed in...